Earnings Call
Sep 1, 2026
Q3 FY2026
EPS Estimate
1.39
EPS Actual
1.36
Post-Earnings Close
$92.04
Earnings Reaction
+1.5%
Medtronic delivered a strong third quarter with 6% organic revenue growth, the highest in 10 quarters, and adjusted EPS of $1.36, beating guidance by $0.03. The standout driver was Cardiac Ablation Solutions, which grew 80% year-over-year with pulsed field ablation (PFA) accounting for 80% of that growth, as the Affera platform and Sphere-9 catheter gained significant market share in a rapidly expanding $13+ billion electrophysiology market. Beyond the headline beat, management articulated a clear multi-year growth acceleration narrative anchored on four "generational growth drivers", PFA, Symplicity renal denervation, Altaviva tibial neurostimulation, and Hugo surgical robot, each with potential to exceed $1 billion in revenue and targeting large, underpenetrated markets. The company also achieved a notable milestone with FDA clearance of Stealth AXiS, a new AI-powered navigation and robotics platform for spine surgery that management believes will materially extend Medtronic's competitive moat by integrating seamlessly into existing surgical workflows where navigation already dominates 70% of U.S. procedures.
Report generated on Aug 31, 2026
AI-generated earnings analysis. Not investment advice.
Chief Executive Officer
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
Read the full MDT analysis
The complete report, with key themes, analyst Q&A summary, notable quotes, and market context — is free with an account. No password, no card.